Mucinous Breast Carcinoma

Introduction to Mucinous Breast Carcinoma

Accounting for approximately 2% of all breast cancer cases, mucinous carcinoma is characterized by the presence of abundant extracellular mucin production, which sets it apart from the more common infiltrating ductal carcinoma. At the molecular level, mucinous breast carcinoma are predominantly of the luminal A intrinsic subtype, exhibiting low levels of genetic instability and rare recurrent amplifications. This unique genomic landscape offers both challenges and opportunities in the pursuit of more effective therapeutic strategies.

Fig.1 Histopathological image of pure mucinous breast cancer (PMBC) (grade 2, H&E)-characteristic cancer cells "nests" foating in abundant extracellular mucus. (Budzik M.P., et al. 2021)

Therapy Development for Mucinous Breast Carcinoma

Researchers are exploring a variety of combination approaches, including standard chemotherapies as well as targeted agents like RANKL inhibitors, to improve outcomes for patients with mucinous breast carcinoma. The use of nanoparticle-based delivery of paclitaxel is also being investigated.

Our Services

Mucinous breast carcinoma is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for mucinous breast carcinoma, including but not limited to the following. 

At Alfa Cytology, our comprehensive suite of oncology services and deep disease-specific expertise provide a powerful platform for accelerating the development of novel mucinous breast carcinoma therapies. From molecular profiling and biomarker discovery to the establishment of robust preclinical models and the systematic evaluation of therapeutic candidates, our team of cancer experts is well-equipped to support researchers and clinicians at every stage of the drug development process. If you are interested in our service, please contact us.